JZJunlin Zhuo

Junlin Zhuo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junlin Zhuo has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control

    by Katie Fisher, Mauro A. Garcia, Giacomo S. Frattari, Chloé Naasz, Junlin Zhuo, Miriam Rosás-Umbert, Lisa L. Dietz, Anna Karina Juhl, Emma Falling Iversen, Rikke Olesen, et al.

    Antiretroviral therapy (ART) interruption typically leads to rapid HIV-1 viral rebound in people with HIV-1. To develop an HIV-1 cure, insight into immunological mechanisms capable of preventing HIV-1 viral rebound is urgently needed. Here, we describe three exceptional post-intervention controllers (PICs) who maintained ART-free virological control for >6.5 years (ongoing), >7.5 years (ongoing) and 2.5 years following administration of broadly neutralizing antibodies. PICs had quantifiable genetically intact/inducible infectious proviral reservoirs that were increasingly clonal and located in nongenic/centromeric chromosomal regions, indicating immune-mediated selection. Potent autologous neutralizing antibodies and polyfunctional HIV-1-specific CD4 + and CD8 + T cell responses, pre-programmed for antigen response, were present before, and persisted during, ART interruption. In one PIC, viral rebound following 2.5 years of ART-free control was associated with accumulated viral mutations that resulted in escape from neutralizing antibody and T cell responses. Collectively, our findings support developing HIV-1 curative strategies aimed at enhancing pre-existing adaptive immune responses.


  • Open Access

    Cellular engagement of the SARS-CoV-2 macrodomain by GS-441524 and enhanced in vitro inhibition by its diphosphorylated metabolite

    by Banhi Biswas, Junlin Zhuo, Jürgen Bosch, Hien Vu, Lorencia Pak, Rameez Raja, Anuradha Roy, Alessandro Panattoni, Michal Maryska, Petr Slavik, et al.

    GS-441524, the parent nucleoside of remdesivir, engages the SARS-CoV-2 macrodomain (Mac1) in cells, and its diphosphate metabolite exhibits enhanced inhibitory activity.


  • High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain

    by Morgan Dasovich, Junlin Zhuo, Jack A. Goodman, Ajit Thomas, Robert Lyle McPherson, Aravinth Kumar Jayabalan, Veronica F. Busa, Shang-Jung Cheng, Brennan A. Murphy, Karli R. Redinger, et al.

    Macrodomains are a class of conserved ADP-ribosylhydrolases expressed by viruses of pandemic concern, including coronaviruses and alphaviruses. Viral macrodomains are critical for replication and virus-induced pathogenesis; therefore, these enzymes are a promising target for antiviral therapy. However, no potent or selective viral macrodomain inhibitors currently exist, in part due to the lack of a high-throughput assay for this class of enzymes. Here we developed a high-throughput ADP-ribosylhydrolase assay using the SARS-CoV-2 macrodomain Mac1. We performed a pilot screen that identified dasatinib and dihydralazine as ADP-ribosylhydrolase inhibitors. Importantly, dasatinib inhibits SARS-CoV-2 and MERS-CoV Mac1 but not the closest human homologue, MacroD2. Our study demonstrates the feasibility of identifying selective inhibitors based on ADP-ribosylhydrolase activity, paving the way for the screening of large compound libraries to identify improved macrodomain inhibitors and to explore their potential as antiviral therapies for SARS-CoV-2 and future viral threats.